Lilly licenses anti-inflammatory from Incyte in deal worth up to $755 million

Lilly has licensed from Incyte worldwide rights to an oral JAK1/JAK2 inhibitor in a Phase II dose-ranging study for rheumatoid arthritis. Under the development and commercialisation pact, Lilly also has rights to certain follow-on compounds.

Lilly has licensed from Incyte worldwide rights to an oral JAK1/JAK2 inhibitor in a Phase II dose-ranging study for rheumatoid arthritis. Under the development and commercialisation pact, Lilly also has rights to certain follow-on compounds.

Lilly will pay $90 million up front and up to $665 million in milestones, as well as tiered double-digit royalties...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Alimentary/Metabolic

More from Therapeutic Category